Advances in Recognition and Treatment of Social Anxiety Disorder: A 10-Year Retrospective
By Murray B. Stein, MD, FRCPC
Obsessive-Compulsive Disorder: Implications of the Efficacy of an SSRI, Paroxetine
By Philip T. Ninan, MD
Treatment of Posttraumatic Stress Disorder: The Impact of Paroxetine
By Jonathan R.T. Davidson, MD
Paroxetine Treatment of Generalized Anxiety Disorder
By David V. Sheehan, MD, MBA, and C. Gloria Mao, PharmD
Treatment of Panic Disorder: Focus on Paroxetine
By Mark H. Pollack, MD and Alicia C. Doyle, BA
Paroxetine Treatment of Major Depressive Disorder
By Martin B. Keller, MD
In Vivo Neuroimaging Correlates of the Efficacy of Paroxetine in the Treatment of Mood and Anxiety Disorders
By Clinton Kilts, PhD
Neuropharmacology of Paroxetine
By Michael J. Owens, PhD, and Charles B. Nemeroff, MD, PhD
Advancing the Treatment of Mood and Anxiety Disorders: The First 10 Years’ Experience with Paroxetine
By Charles B. Nemeroff, MD, PhD
Gender-Specific Differences in Depression and Treatment Response
By Susan G. Kornstein, MD, Diane M. E. Sloan, PharmD, and Michael E. Thase, MD
New Advances in the Management of Anxiety Disorders
By Mark H. Pollack, MD
Neurobiology and Mechanisms of Antidepressant Treatment Response in Anxiety
By Philip T. Ninan, MD, Sarah A. Feigon, PhD, and Bettina Knight, RN
Strategies for Treatment-Resistant Depression
By Christos Ballas, MD, Jeffrey P. Staab, MD, MS, and Dwight L. Evans, MD
Long-Term Antidepressant Treatment
By Katia K. Delrahim, BA, Rachel Maddux, BA, and Mark Hyman Rapaport, MD
Remission as the Critical Outcome of Depression Treatment
By Michael E. Thase, MD, Diane M. E. Sloan, PharmD, and Susan G. Kornstein, MD
New Developments in Depression and Anxiety Disorders
Raising the Expectations of Long-Term Treatment Strategies in Anxiety Disorders
Can We Distinguish Anxiety From Depression?
By David S. Baldwin, FRCPsych, Dwight L. Evans, MD, Robert M. A. Hirschfeld, MD, and Siegfried Kasper, MD
Unraveling the Diagnostic Clues of Depression and GAD: The Primary Care Challenge
By Johan A. den Boer, MD, Dwight L. Evans, MD, Sing Lee, MD, PhD, and Rafael Salin-Pascual, MD
Algorithms in Clinical Psychiatry: A Stepped Approach Toward the Path to Recovery
By Madhukar Trivedi, MD
Mechanism of Action of Antidepressants
By Francesc Artigas, PhD, David J. Nutt, MD, PhD, and Richard Shelton, MD
Depression in the Elderly
By William M. McDonald, MD, Carl Salzman, MD, and Alan F. Schatzberg, MD
Coping With Somatic Comorbidities: Striving for Complete Recovery
By Christer Allgulander, MD, and Siegfried Kasper, MD
Generalized Anxiety Disorder: Raising the Expectations of Treatment
By Christer Allgulander, MD, and David V. Sheehan, MD, MBA
Long-Term Treatment Strategies in Affective Disorders
Recent Advances in the Neurobiology of Depression
Remission: Today’s Target in the Treatment of Mood and Anxiety Disorders
Intermittent Fluoxetine Dosing in the Treatment of Women With Premenstrual Dysphoria
By Meir Steiner, MD, PhD, FRCPC, Marilyn Korzekwa, MD, FRCPC, John Lamont, MD, MSc, FRCSC, and Annette Wilkins, BA
Pharmacokinetics, Drug Interactions, and Tolerability of Paroxetine and Paroxetine CR
By Lindsay DeVane, PharmD
Efficacy and Tolerability of Controlled-Release Paroxetine
By Robert N. Golden, MD
A Discussion on the Methodologies Used to Evaluate Antidepressants
MODERATOR: Jan A. Fawcett, MD
DISCUSSANTS: Norman Sussman, MD Jeffrey H. Newcorn, MD
Risperidone: Review of Its Therapeutic Utility in Depression
By Joyce E. Myers, MD, and Michael E. Thase, MD
A Model to Explain the Therapeutic Effects of Serotonin Reuptake Inhibitors: The Role of 5-HT2 Receptors
By Mikael Landén, MD, PhD, and Michael E. Thase, MD
Anxiety and Other Emotional Factors in Noncardiac Chest Pain
By Kamila S. White, PhD and Susan D. Raffa, MA
Economic Impacts of Anxiety Disorders
By Ernst R. Berndt, PhD and Tamar Sisitsky, MA
Anxiety Disorders
Overview:
Vast Progress but a Long Journey Ahead
By Tracey M. Boudine
Psychiatric Bulletin:
Late-Breaking Clinical News